Table 5 Percentage of sensitivity at 90% specificity at the different CRC stages for CEA or combinations of NuQ® biomarkers
From: Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer
% Sensitivity at 90% specificity | |||
|---|---|---|---|
CRC | CEA | Combination of 4 NuQ® assays | Combination of 4 NuQ® assays age adjusted |
All stages | 35 | 74 | 91 |
Stage I | 0 | 75 | 75 |
Stage II | 14 | 86 | 86 |
Stage III | 57 | 71 | 100 |
Stage IV | 60 | 60 | 100 |